RATIONAL APPROACH TO SARS THERAPY IN CHILDREN WITH RECURRENT INFECTIONS OF THE RESPIRATORY TRACT: COMPARATIVE ANALYSIS OF EFFICACY AND SAFETY OF THERAPEUTIC AND PREVENTIVE REGIMENS WITH GENFERON® LITE AND ARBIDOL® / РАЦИОНАЛЬНЫЙ ПОДХОД К ТЕРАПИИ ОРВИ У ДЕТЕЙ С РЕКУРРЕНТНЫМИ ИНФЕКЦИЯМИ ОРГАНОВ РЕСПИРАТОРНОГО ТРАКТА: СРАВНИТЕЛЬНОЕ ИССЛЕДОВАНИЕ ЭФФЕКТИВНОСТИ И БЕЗОПАСНОСТИ ЛЕЧЕБНЫХ И ПРОФИЛАКТИЧЕСКИХ СХЕМ ТЕРАПИИ ПРЕПАРАТАМИ ГЕНФЕРОН® ЛАЙТ И АРБИДОЛ®

Selection of rational therapy of SARS in children with recurrent infections of the respiratory tract organs requires an individual approach depending on each patient characteristics. The article presents data of comparative randomized prospective study of medications Genferon® Light and Arbidol® efficacy and safety in SARS treatment and prevention in the group frequently and chronically ill children. The study included 64 children aged 3 to 6 years from 4 Russian research centers with SARS, symptoms lasting no more than 48 hours and infectious index higher than 1,1. Patients of the main groups received Genferon® Light rectally, one suppository 2 times a day for 10 days parallel with the standard therapy, followed by prophylactic scheme: one suppository in dose of 125 000 IU 1 time a day for 3 weeks. Patients of the comparison group received Arbidol® 50 mg 4 times a day for 5 days, then prophylactic scheme: 50 mg 2 times a week for 3 weeks. Monitoring of patients, laboratory and immunological parameters control was performed for 180 days. Analysis of the data showed that Genferon® Light and Arbidol® have a good level of safety and similar efficacy in acute respiratory viral infections treatment in children with recurrent respiratory infections, that allows to relief main disease symptoms. Genferon® Light in comparison with Arbidol® has higher preventive activity against SARS repeated episodes in children with recurrent respiratory tract infections for a period equal to 140 days of therapy.